197663-30-2

Upstream product

• 100-02-7 4-nitro-phenol 
• 197663-09-5 N-tetradecanoyl-O-<2-deoxy-2-<(R)-3-tetradecanoyloxytetradecanoylamino>-β-D-glucopyranosyl>-L-seryl-β-alanine 
• 197663-32-4 N-tetradecanoyl-O-<3,4,6-tri-O-acetyl-2-deoxy-2-<(R)-3-tetradecanoyloxytetradecanoylamino>-β-D-glucopyranosyl>-L-seryl-β-alanine 
• 186753-98-0 N-tetradecanoyl-O-[3,4,6-tri-O-acetyl-2-deoxy-2-[(R)-3-tetradecanoyloxytetradecanoylamino]-β-D-glucopyranosyl]-L-serine 

Relevant academic research and scientific papers

Synthesis of cancer peptide antigen-lipid A analog conjugates for synthetic vaccines

Conjugates 6 and 7 of cancer peptide antigen with N-tetradecanoyl L- serine-β-alanine-containing D-glucosamine derivative structurally related to lipid A as an immunoadjuvant were synthesized for the development of totally synthetic vaccines against cancers. The mitogenic activities of compounds 6 and 7 were stronger than that of lipid A analog 3.

Synthesis of Tn, sialyl Tn and HIV-1-derived peptide antigen conjugates having a lipid a analog as an immunoadjuvant for synthetic vaccines

Conjugates (3-5) of Tn, sialyl Tn and HIV-1-derived peptide antigen with a N-tetradecanoyl L-serine-β-alanine-containing D-glucosamine derivative, structurally related to lipid A, as an immunoadjuvant for the development of totally synthetic vaccines against cancers or HIV were synthesized. The mitogenic activity of compounds 3, 4 and 5 was stronger than that of lipid A analogs (1, 2).

Synthesis of Tn, and sialyl Tn antigen-lipid a analog conjugates for synthetic vaccines

Conjugates of Tn and sialyl Tn antigen with N-teradecanoyl L-seryl-β- alanine-containing 9-glucosamine derivatives structurally related to lipid A as a immunoadjuvant were synthesized for the development of totally synthetic vaccines against cancers or HIV.